Ranibizumab and stroke

Ophthalmology

Volumn 117, Issue 9, 2010, Pages 1860-

  Ueta, Takashi ^a   Yanagi, Yasuo ^a   Tamaki, Yasuhiro ^a   Yamaguchi, Takuhiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

CLINICAL TRIAL; COHORT ANALYSIS; DRUG SAFETY; HUMAN; INCIDENCE; LETTER; LOADING DRUG DOSE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; STROKE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS; MACULAR DEGENERATION; RETREATMENT; RISK FACTORS; STROKE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77956311268     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.05.005     Document Type: Letter

References (2)

1. D.S. Boyer, J.S. Heier, and D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
2. T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi Cerebrovascular accidents in ranibizumab Ophthalmology 116 2009 362